inVentiv Health Clinical UK Ltd Sample Clauses

inVentiv Health Clinical UK Ltd. For itself and on behalf of Sponsor under a Master Limited Agency Agreement/Za sebe a jménem Zadavatele podle Rámcové smlouvy o omezeném jednatelství By/Jméno: Sign Here/Podepište zde Print Name/ Jméno tiskacím písmem: Title/ Funkce: Date/Datum: FAKULTNÍ NEMOCNICE KRÁLOVSKÉ VINOHRADY By/Jméno: Sign Here/Podepište zde Print Name/ Jméno tiskacím písmem: Xxx. XXXx. Xxxxxx Xxxxx, Ph.D., MHA Title/ Funkce: Director/ředitel Date/Datum: PRINCIPAL INVESTIGATOR/HLAVNÍ ZKOUŠEJÍCÍ By/Jméno: Sign Here/Podepište zde Print Name/ Jméno tiskacím písmem: XXXx. Xxxxx Xxxxxxxx, Ph.D. Title/Funkce: Principal Investigator/hlavní zkoušející Date/Datum: Schedules: Přílohy: Schedule A - Payment Schedule and Budget Příloha A – Rozvrh plateb a rozpočet SCHEDULE A-PAYMENT SCHEDULE & BUDGET PŘÍLOHAA-ROZVRH PLATEB AROZPOČET Sponsor’s Authorized Payment Agent (“APA”): Zadavatelem pověřený zástupce pro platby (authorized payment agent, APA): Payments shall be made to the following payee/ Platby budou vyplaceny následujícímu příjemci: Payee Name/ Jméno příjemce plateb: Fakultní nemocnice Královské Vinohrady Tax ID Number/ DIČ: CZ00064173 Method of Payment: APA shall make payments as follows/ Způsob platby: APA uhradí platby následujícím způsobem: Direct Deposit/ Bankovní převod: Bank’s Name/ Název banky: Česká národní banka Bank’s Location/ Adresa banky: Xx Xxxxxxx 00, 000 00 Xxxxx 0, Xxxxx Xxxxxxxx Account Number/ Číslo účtu: 16334101/0710 IBAN code/IBAN kód: XX00 0000 0000 0000 0000 0000 SWIFT code/SWIFT kód: XXXXXXXX Name of Account Holder/ Jméno majitele účtu: Fakultní nemocnice Královské Vinohrady Invoices: All invoices should be addressed/made to and includes Protocol ID, Investigator Name and Site Name. ( , PI Mocikova, FNKV) Registration Number: Faktury: Všechny faktury musí být vystaveny na níže uvedenou adresu a obsahovat číslo protokolu, jméno zkoušejícího a název pracoviště. ( , PI Mocikova, FNKV) IČO: Invoices should be uploaded directly via the DrugDev Site Portal (instructions will be provided under separate cover), submitted Faktury nahrávejte přímo na portál DrugDev (pokyny budou zaslány v samostatném dopise), zasílejte v elektronické podobě na adresu electronically to or submitted via nebo zasílejte faxem na číslo či poštou na adresu: facsimile to or sent by mail to: Invoices submitted via the portal or email will be immediately acknowledged with a reference number for future reference. Fakturám zaslaným prostřednictvím portálu nebo e-mailem bude ihned po přijetí přiděl...
AutoNDA by SimpleDocs

Related to inVentiv Health Clinical UK Ltd

  • Technology Research Analyst Job# 1810 General Characteristics Maintains a strong understanding of the enterprise’s IT systems and architectures. Assists in the analysis of the requirements for the enterprise and applying emerging technologies to support long-term business objectives. Responsible for researching, collecting, and disseminating information on emerging technologies and key learnings throughout the enterprise. Researches and recommends changes to foundation architecture. Supports research projects to identify and evaluate emerging technologies. Interfaces with users and staff to evaluate possible implementation of the new technology in the enterprise, consistent with the goal of improving existing systems and technologies and in meeting the needs of the business. Analyzes and researches process of deployment and assists in this process.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Research, Science and Technology Cooperation 1. The aims of cooperation in research, science and technology, carried out in the mutual interest of the Parties and in compliance with their policies, will be: (a) to build on existing agreements already in place for cooperation on research, science and technology; (b) to encourage, where appropriate, government agencies, research institutions, universities, private companies and other research organizations in the Parties to conclude direct arrangements in support of cooperative activities, programs or projects within the framework of this Agreement, specially related to trade and commerce; and (c) to focus cooperative activities towards sectors where mutual and complementary interests exist, with special emphasis on information and communication technologies and software development to facilitate trade between the Parties. 2. The Parties will encourage and facilitate, as appropriate, the following activities including, but not limited to:

  • Drug and Alcohol Testing – Safety-Sensitive Functions A. Employees required to have a Commercial Driver’s License (CDL) are subject to pre-employment, post-accident, random and reasonable suspicion testing in accordance with the U.S. Department of Transportation rules, Coast Guard Regulations (46 CFR Part 16) or the Federal Omnibus Transportation Employee Testing Act of 1991. The testing will be conducted in accordance with current Employer policy.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • HEALTH PROGRAM 3701 Health examinations required by the Employer shall be provided by the Employer and shall be at the expense of the Employer. 3702 Time off without loss of regular pay shall be allowed at a time determined by the Employer for such medical examinations and laboratory tests, provided that these are performed on the Employer’s premises, or at a facility designated by the Employer. 3703 With the approval of the Employer, a nurse may choose to be examined by a physician of her/his own choice, at her/his own expense, as long as the Employer receives a statement as to the fitness of the nurse from the physician. 3704 Time off for medical and dental examinations and/or treatments may be granted and such time off, including necessary travel time, shall be chargeable against accumulated income protection benefits.

  • DRUG/ALCOHOL TESTING 11.1 The parties agree that the maintenance of a drug/alcohol free work place is a goal of both the College and the Union. Employees are prohibited from possession, consumption and/or being under the influence of a controlled substance/alcohol while on the College’s premises or during time paid by the employer. Violations of this prohibition may result in a disciplinary action up to and including termination.

  • DRUG AND ALCOHOL TESTING Employees may be tested for drugs and/or alcohol pursuant to the provisions of the Employer's Drug and Alcohol Testing Policy which is attached hereto and made a part of this Agreement as if more fully set forth herein.

Time is Money Join Law Insider Premium to draft better contracts faster.